Circadian Mechanisms, Glucose, and CV Risks in T1D (NCT06624046)
Circadian Mechanisms of Glycemic Control and Cardiovascular Risk in Adults With Type 1 Diabetes
🩺 Plain-English Summary (8th-Grade Level)
People with type 1 diabetes are disproportionately affected by cardiovascular disease (CVD). Short and irregular sleep have been associated with cardiovascular risk in this population. Improving sleep regularity has been associated with improved glycemic markers however mechanisms by which improving sleep regularity improves metabolic and cardiovascular health is not known. The investigators propose to conduct a mechanistic study using a sleep stability manipulation. This proposal will advance the understanding of mechanisms by which improving sleep regularity influences glycemic control and cardiovascular risk in T1D.
Who can join: Review the eligibility criteria below.
Location: University of Illinois Chicago — Chicago, Illinois
Age range: 18 Years to 50 Years
🧪 Interventions in This Study
- Sleep stability intervention (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Illinois Chicago — Chicago, Illinois
📞 Contact the Study Coordinator
Phone: (312) 996-7903
Email: pmartyn@uic.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Type 1 Diabetes (T1D)
- PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study — San Francisco, California
- Technology Knowledge Optimization for Type 1 Diabetes in Schools — Pittsburgh, Pennsylvania
- Feasibility Study of a Continuous Glucose-Ketone Monitoring Device in People With Type 1 Diabetes — Palo Alto, California
- Pilot of Food Is Medicine Interventions to Reduce Cardiovascular Disease Risk in Children With Food Insecurity and Diabetes — Providence, Rhode Island
- App-Based Certified Diabetes Education Therapy (AB-CDE) — La Jolla, California
- CKM For Safe Use of SGLT2i in Type 1 Diabetes — La Jolla, California
Explore by condition: All Type 1 Diabetes (T1D) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.